Biochemical markers of aging for longitudinal studies in humans

Epidemiologic Reviews

Volumn 35, Issue 1, 2013, Pages 132-151

  Engelfriet, Peter M ^a   Jansen, Eugène H J M ^a   Picavet, H Susan J ^a   Dollé, Martijn E T ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

aging; biomarkers; longitudinal studies

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; ALPHA TOCOPHEROL; AMYLOID A PROTEIN; ASCORBIC ACID; BIOCHEMICAL MARKER; CAVEOLIN 1; DNA POLYMERASE; EOTAXIN; GLUCOSE; GLUTATHIONE PEROXIDASE; GLYCOSYLATED HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; ISOPROSTANE DERIVATIVE; LEPTIN; LIOTHYRONINE; LUTEINIZING HORMONE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PENTOSIDINE; REACTIVE OXYGEN METABOLITE; RETINOL; SIRTUIN 1; SIRTUIN 2; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE 1; THYROTROPIN; BIOLOGICAL MARKER; GENETIC MARKER; PROTEIN;

AGING; ARTICLE; B LYMPHOCYTE; BLOOD CLOTTING; BLOOD SAMPLING; COMPLEMENT SYSTEM; DNA REPAIR; ENERGY METABOLISM; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONE RELEASE; HUMAN; LIFE EXPECTANCY; LIPID PEROXIDATION; LONGITUDINAL STUDY; METABOLISM; MORBIDITY; MORTALITY; OXIDATIVE STRESS; OXYGEN TRANSPORT; PANCREAS ISLET BETA CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; REPRODUCTION; SENESCENCE; T LYMPHOCYTE; TELOMERE; ARTERIAL STIFFNESS; GENETIC MARKER; INFLAMMATION; KIDNEY FUNCTION TEST; LIPID METABOLISM; LUNG FUNCTION TEST;

AGING; BIOMARKERS; BLOOD COAGULATION; DNA REPAIR; ENERGY METABOLISM; GENETIC MARKERS; HOMEOSTASIS; HUMANS; INFLAMMATION; KIDNEY FUNCTION TESTS; LIPID METABOLISM; LONGITUDINAL STUDIES; OXIDATIVE STRESS; PROTEINS; RESPIRATORY FUNCTION TESTS; TELOMERE; VASCULAR STIFFNESS;

EID: 84874455383     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxs011     Document Type: Article

References (211)

1. Hasty P, Campisi J, Hoeijmakers J, et al. Aging and genome maintenance: lessons from the mouse? Science. 2003; 299(5611):1355-1359.
2. Blumenthal HT. The aging-disease dichotomy: true or false? J Gerontol A Biol Sci Med Sci. 2003;58(2):138-145.
3. Newman AB, Ferrucci L. Call for papers: aging versus disease. J Gerontol A Biol Sci Med Sci. 2009;64(11):1163-1164.
4. Sprott RL. Biomarkers of aging and disease: introduction and definitions. Exp Gerontol. 2010;45(1):2-4.
5. Strehler BL. Time, Cells, and Aging. New York, NY: Academic Press; 1962.
6. Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier 2011.
7. Kenyon CJ. The genetics of ageing. Nature. 2010; 464(7288):504-512.
8. Lawless C, Wang C, Jurk D, et al. Quantitative assessment of markers for cell senescence. Exp Gerontol. 2010;45(10): 772-778.
9. Liu L, Rando TA. Aging of stem cells: intrinsic changes and environmental influences. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011:141-161.
10. Zou H, Stoppani E, Volonte D, et al. Caveolin-1, cellular senescence and age-related diseases. Mech Ageing Dev. 2011;132(11-12):533-542.
11. Coppe JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118.
12. Langeberg WJ, Tahir SA, Feng Z, et al. Association of caveolin-1 and-2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate. 2010;70(9):1020-1035.
13. Atwater S, Corash L. Advances in leukocyte differential and peripheral blood stem cell enumeration. Curr Opin Hematol. 1996;3(1):71-76.
14. Masouleh BK, Baraniskin A, Schmiegel W, et al. Quantification of circulating endothelial progenitor cells in human peripheral blood: establishing a reliable flow cytometry protocol. J Immunol Methods. 2010;357(1-2):38-42.
15. Mariucci S, Rovati B, Bencardino K, et al. Flow cytometric detection of circulating endothelial cells and endothelial progenitor cells in healthy subjects. Int J Lab Hematol. 2010;32(1):e40-e48.
16. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloprotei-nases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221-233.
17. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
18. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008;88(2):557-579.
19. Zhu H, Belcher M, van der Harst P. Healthy aging and disease: role for telomere biology? Clin Sci (Lond). 2011;120(10):427-440.
20. Demissie S, Levy D, Benjamin EJ, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell. 2006;5(4):325-330.
21. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007; 8(9):703-713.
22. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11(5):319-330.
23. Aviv A. Leukocyte telomere dynamics, human aging, and life span. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011:163-176.
24. Samani NJ, van der Harst P. Biological ageing and cardiovascular disease. Heart. 2008;94(5):537-539.
25. Mather KA, Jorm AF, Parslow RA, et al. Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci. 2011;66(2):202-213.
26. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(7):566-571.
27. Cawthon RM, Smith KR, O'Brien E, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393-395.
28. Martin-Ruiz C, Dickinson HO, Keys B, et al. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol. 2006;60(2):174-180.
29. Martin-Ruiz CM, Gussekloo J, van Heemst D, et al. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4(6):287-290.
30. Martin-Ruiz C, Jagger C, Kingston A, et al. Assessment of a large panel of candidate biomarkers of ageing in the Newcastle 85+ study. Mech Ageing Dev. 2011;132(10): 496-502.
31. Epel ES, Merkin SS, Cawthon R, et al. The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging (Albany NY). 2009;1(1): 81-88.
32. Epel ES, Lin J, Wilhelm FH, et al. Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology. 2006;31(3):277-287.
33. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475-1485.
34. Loft S, Vistisen K, Ewertz M, et al. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13(12):2241-2247.
35. Simm A, Nass N, Bartling B, et al. Potential biomarkers of ageing. Biol Chem. 2008;389(3):257-265.
36. Ashok BT, Ali R. Binding of circulating antibodies to reactive oxygen species modified-DNA and detecting DNA damage by a monoclonal antibody probe. Mech Ageing Dev. 1998;103(1):69-80.
37. Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature. 2008;454(7208):1065-1071.
38. Haigis MC, Sinclair DA. Sirtuins in aging and age-related diseases. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011:243-274.
39. Guarente L. Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med. 2011;364(23):2235-2244.
40. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10(12):819-823.
41. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-430.
42. Barrett KE, Barman SM, Boitano S, et al. Ganong's Review of Medical Physiology. 24th ed. New York, NY: McGraw-Hill Medical; 2012.
43. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707- 713.
44. Perez-Castro C, Renner U, Haedo MR, et al. Cellular and molecular specificity of pituitary gland physiology. Physiol Rev. 2012;92(1):1-38.
45. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol. 2007;211(2):173-180.
46. Sherlock M, Toogood AA. Aging and the growth hormone/insulin like growth factor-I axis. Pituitary. 2007;10(2): 189-203.
47. Sonntag WE, Csiszar A, de Cabo R, et al. Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies. J Gerontol A Biol Sci Med Sci. 2012;67(6):587-598.
48. Yashin AI, Ukraintseva SV, Arbeev KG, et al. Maintaining physiological state for exceptional survival: what is the normal level of blood glucose and does it change with age? Mech Ageing Dev. 2009;130(9):611-618.
49. Yashin AI, Arbeev KG, Akushevich I, et al. Exceptional survivors have lower age trajectories of blood glucose: lessons from longitudinal data. Biogerontology. 2010; 11(3):257-265.
50. Pani LN, Korenda L, Meigs JB, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008;31(10):1991-1996.
51. Cerami A, Vlassara H, Brownlee M. Glucose and aging. Sci Am. 1987;256(5):90-96.
52. Halter JB. Aging and insulin secretion. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011:373-384.
53. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab. 2007;293(1): E1-E15.
54. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284(1):E7-E12.
55. Faerch K, Brons C, Alibegovic AC, et al. The disposition index: adjustment for peripheral vs. hepatic insulin sensitivity? J Physiol. 2010;588(Pt 5):759-764.
56. Szoke E, Shrayyef MZ, Messing S, et al. Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance. Diabetes Care. 2008;31(3):539-543.
57. Florido R, Tchkonia T, Kirkland JL. Aging and adipose tissue. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011:119-140.
58. Arai Y, Takayama M, Abe Y, et al. Adipokines and aging. J Atheroscler Thromb. 2011;18(7):545-550.
59. Lieb W, Beiser AS, Vasan RS, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302(23): 2565-2572.
60. Lee EB. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci. 2011;1243:15-29.
61. Migeon CJ, Keller AR, Lawrence B, et al. Dehydroepian-drosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab. 1957;17(9):1051-1062.
62. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315(24):1519-1524.
63. Cappola AR, Xue QL, Walston JD, et al. DHEAS levels and mortality in disabled older women: the Women's Health and Aging Study I. J Gerontol A Biol Sci Med Sci. 2006; 61(9):957-962.
64. Franz CE, O'Brien RC, Hauger RL, et al. Cross-sectional and 35-year longitudinal assessment of salivary cortisol and cognitive functioning: the Vietnam Era twin study of aging. Psychoneuroendocrinology. 2011;36(7):1040-1052.
65. Tomiyama AJ, O'Donovan A, Lin J, et al. Does cellular aging relate to patterns of allostasis? An examination of basal and stress reactive HPA axis activity and telomere length. Physiol Behav. 2012;106(1):40-45.
66. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science. 2010;328 (5976):321-326.
67. Knecht E, Aguado C, Carcel J, et al. Intracellular protein degradation in mammalian cells: recent developments. Cell Mol Life Sci. 2009;66(15):2427-2443.
68. De Matteis MA, Luini A. Mendelian disorders of membrane trafficking. N Engl J Med. 2011;365(10):927-938.
69. Soskic V, Groebe K, Schrattenholz A. Nonenzymatic post-translational protein modifications in ageing. Exp Gerontol. 2008;43(4):247-257.
70. Morimoto RI. Stress, aging, and neurodegenerative disease. N Engl J Med. 2006;355(21):2254-2255.
71. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519-529.
72. Marini M, Lapalombella R, Canaider S, et al. Heat shock response by EBV-immortalized B-lymphocytes from centenarians and control subjects: a model to study the relevance of stress response in longevity. Exp Gerontol. 2004;39(1):83-90.
73. Ambra R, Mocchegiani E, Giacconi R, et al. Characterization of the hsp70 response in lymphoblasts from aged and centenarian subjects and differential effects of in vitro zinc supplementation. Exp Gerontol. 2004;39(10):1475-1484.
74. Westerheide SD, Anckar J, Stevens SM, Jr, et al. Stress-inducible regulation of heat shock factor 1 by the deacety-lase SIRT1. Science. 2009;323(5917):1063-1066.
75. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90-94.
76. Glei DA, Goldman N, Lin YH, et al. Age-related changes in biomarkers: longitudinal data from a population-based sample. Res Aging. 2011;33(3):312-326.
77. Yashin AI, Akushevich IV, Arbeev KG, et al. Insights on aging and exceptional longevity from longitudinal data: novel findings from the Framingham Heart Study. Age (Dordr). 2006;28(4):363-374.
78. Arbeev KG, Ukraintseva SV, Akushevich I, et al. Age trajectories of physiological indices in relation to healthy life course. Mech Ageing Dev. 2011;132(3):93-102.
79. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011; 60(10):2441-2449.
80. Frayn KN, Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci (Lond). 1996;90(4):243-253.
81. Charles MA, Fontbonne A, Thibult N, et al. High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris Prospective Study. Am J Epidemiol. 2001;153(3): 292-298.
82. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med. 2011;365(19):1812-1823.
83. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11:298-300.
84. Perez VI, Bokov A, Van Remmen H, et al. Is the oxidative stress theory of aging dead? Biochim Biophys Acta. 2009;1790(10):1005-1014.
85. Buijsse B, Feskens EJ, Moschandreas J, et al. Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). Eur J Cardiovasc Prev Rehabil. 2007; 14(4):495-500.
86. Calabrese V, Cornelius C, Leso V, et al. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim Biophys Acta. 2012;1822(5):729-736.
87. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44-84.
88. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6): 2294-2299.
89. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365(6):537-547.
90. Bosch-Marce M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res. 2007;101(12):1310-1318.
91. Sorond FA, Shaffer ML, Kung AL, et al. Desferroxamine infusion increases cerebral blood flow: a potential association with hypoxia-inducible factor-1. Clin Sci (Lond). 2009;116(10):771-779.
92. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28(4):505-513.
93. Guralnik JM, Ershler WB, Schrier SL, et al. Anemia in the elderly: a public health crisis in hematology. Hematology Am Soc Hematol Educ Program. 2005:528-532.
94. den Elzen WP, Willems JM, Westendorp RG, et al. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. CMAJ. 2009;181(3-4):151-157.
95. Haslam A, Hausman DB, Johnson MA, et al. Prevalence and predictors of anemia in a population-based study of octogenarians and centenarians in Georgia. J Gerontol A Biol Sci Med Sci. 2012;67(1):100-106.
96. Vanasse GJ, Berliner N. Anemia in elderly patients: an emerging problem for the 21st century. Hematology Am Soc Hematol Educ Program. 2010;2010:271-275.
97. Ershler WB, Sheng S, McKelvey J, et al. Serum erythropoi-etin and aging: a longitudinal analysis. J Am Geriatr Soc. 2005;53(8):1360-1365.
98. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348-359.
99. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167-1173.
100. Tantry US, Gurbel PA. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol. 2011; 8(10):572-579.
101. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology. 2011; 43(7):682-692.
102. Pawelec G. Immunosenescence comes of age. Symposium on aging research in immunology: the impact of genomics. EMBO Rep. 2007;8(3):220-223.
103. Dowling MR, Hodgkin PD. Why does the thymus involute? A selection-based hypothesis. Trends Immunol. 2009; 30(7):295-300.
104. Miller JF. The golden anniversary of the thymus. Nat Rev Immunol. 2011;11(7):489-495.
105. Chen J, Li J, Lim FC, et al. Maintenance of naive CD8 T cells in nonagenarians by leptin, IGFBP3 and T3. Mech Ageing Dev. 2010;131(1):29-37.
106. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119-125.
107. Wick G, Grubeck-Loebenstein B. The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol. 1997;32(4-5): 401-413.
108. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation. 2003;107(1):139-146.
109. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410-1422.
110. Werner N, Nickenig G. Endothelial progenitor cells in health and atherosclerotic disease. Ann Med. 2007;39(2): 82-90.
111. Kunz GA, Liang G, Cuculi F, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J. 2006;152(1):190-195.
112. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999;34(3): 631-638.
113. Kohan DE, Rossi NF, Inscho EW, et al. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011;91(1):1-77.
114. Laughlin GA, Cummins KM, Wassel CL, et al. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012;59(19):1688-1696.
115. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev. 2009;89(3):957-989.
116. Biernacka A, Frangogiannis NG. Aging and cardiac fibrosis. Aging Dis. 2011;2(2):158-173.
117. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009;54(18):1674-1682.
118. Martos R, Baugh J, Ledwidge M, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11(2):191-197.
119. Barasch E, Gottdiener JS, Aurigemma G, et al. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2011;4(6):733-739.
120. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655-663.
121. Daniels LB, Clopton P, Jiang K, et al. Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels. J Card Fail. 2010;16(2):93-98.
122. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55 (19):2140-2147.
123. de Lemos JA, McGuire DK, Khera A, et al. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J. 2009; 157(4):746-753.
124. Macheret F, Boerrigter G, McKie P, et al. Pro-B-type natri-uretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011;57(12):1386-1395.
125. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494- 2502.
126. Fradley MG, Larson MG, Cheng S, et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol. 2011;108(9):1341-1345.
127. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503-2512.
128. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009; 324(5923):98-102.
129. Kajstura J, Gurusamy N, Ogorek B, et al. Myocyte turnover in the aging human heart. Circ Res. 2010;107(11):1374-1386.
130. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocar-dial biology. Circ Res. 2011;109(8):941-961.
131. Taylor NAS. Pulmonary function in aging humans. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011: 421-443.
132. Klaestrup E, Trydal T, Pedersen JF, et al. Reference intervals and age and gender dependency for arterial blood gases and electrolytes in adults. Clin Chem Lab Med. 2011;49(9): 1495-1500.
133. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173-180.
134. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 2009;34(1):95-102.
135. Betsuyaku T, Kuroki Y, Nagai K, et al. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J. 2004;24(6):964-970.
136. Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663-2670.
137. Andersen CU, Hilberg O, Mellemkjaer S, et al. Apelin and pulmonary hypertension. Pulm Circ. 2011;1(3):334-346.
138. Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010;152(9):561-567.
139. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
140. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-470.
141. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
142. Stevens LA, Manzi J, Levey AS, et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis. 2007;50(1):21-35.
143. Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiol. 2011;119(suppl 1):1-5.
144. Weinert LS, Camargo EG, Soares AA, et al. Glomerular filtration rate estimation: performance of serum cystatin C-based prediction equations. Clin Chem Lab Med. 2011; 49(11):1761-1771.
145. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534-2543.
146. Kuro-o M. Klotho and the aging process. Korean J Intern Med. 2011;26(2):113-122.
147. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167(9):879-885.
148. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120(18): 1784-1792.
149. Cooper C, Melton LJ, 3rd. Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992;3(6):224-229.
150. Lotz MK, Carames B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. Nat Rev Rheumatol. 2011;7(10):579-587.
151. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213(3):626-634.
152. Loeser RF. Aging and osteoarthritis. Curr Opin Rheumatol. 2011;23(5):492-496.
153. Kraus VB. Biomarkers in osteoarthritis. Curr Opin Rheumatol. 2005;17(5):641-646.
154. Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum. 1999;42(11):2356-2564.
155. Mobasheri A. Applications of proteomics to osteoarthritis, a musculoskeletal disease characterized by aging. Front Physiol. 2011;2:108.
156. Gharbi M, Deberg M, Henrotin Y. Application for proteomic techniques in studying osteoarthritis: a review. Front Physiol. 2011;2:90.
157. Gagliano N, Grizzi F, Annoni G. Mechanisms of aging and liver functions. Dig Dis. 2007;25(2):118-123.
158. Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4): 1363-1370.
159. Alway SE, Morisette MR, Siu PM. Aging and apoptosis in muscle. In: Masoro EJ, Austad SN, eds. Handbook of the Biology of Aging. Amsterdam, The Netherlands: Elsevier; 2011:63-118.
160. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382): 463-468.
161. Pedersen BK. A muscular twist on the fate of fat. N Engl J Med. 2012;366(16):1544-1545.
162. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
163. van Dijk EJ, Prins ND, Hofman A, et al. Plasma beta amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiol Aging. 2007;28(5):707-712.
164. Johnson TE. Recent results: biomarkers of aging. Exp Gerontol. 2006;41(12):1243-1246.
165. Kirkwood TB. A systematic look at an old problem. Nature. 2008;451(7179):644-647.
166. Cohen AW, Hnasko R, Schubert W, et al. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004; 84(4):1341-1379.
167. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185-194.
168. Hansson J, Lind L, Hulthe J, et al. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil. 2009;16(3):297-303.
169. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1): 60-68.
170. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17. (doi:10.1017/ S1462399408000719).
171. Bakaysa SL, Mucci LA, Slagboom PE, et al. Telomere length predicts survival independent of genetic influences. Aging Cell. 2007;6(6):769-774.
172. Landi F, Capoluongo E, Russo A, et al. Free insulin-like growth factor-I and cognitive function in older persons living in community. Growth Horm IGF Res. 2007; 17(1):58-66.
173. Dik MG, Pluijm SM, Jonker C, et al. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging. 2003;24(4):573-581.
174. Crimmins E, Vasunilashorn S, Kim JK, et al. Biomarkers related to aging in human populations. Adv Clin Chem. 2008;46:161-216.
175. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond). 2011;121(2):43-55.
176. Cappola AR, Xue QL, Fried LP. Multiple hormonal deficiencies in anabolic hormones are found in frail older women: the Women's Health and Aging studies. J Gerontol A Biol Sci Med Sci. 2009;64(2):243-248.
177. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292-295.
178. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-1737.
179. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol. 2000;143(3):293-311.
180. Liu DH, Wang XM, Zhang LJ, et al. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci. 2007;20(1): 33-40.
181. Vanhooren V, Dewaele S, Libert C, et al. Serum N-glycan profile shift during human ageing. Exp Gerontol. 2010; 45(10):738-743.
182. Whayne TF, Alaupovic P, Curry MD, et al. Plasma apolipo-protein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography. Atherosclerosis. 1981;39(3):411-424.
183. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. NIH Publication No. 01-3670. Bethesda, MD: National Heart, Lung, and Blood Institute; 2001.
184. Gil L, Siems W, Mazurek B, et al. Age-associated analysis of oxidative stress parameters in human plasma and erythro-cytes. Free Radic Res. 2006;40(5):495-505.
185. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia. 2000;43(5):550-557.
186. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003;42(4):318-343.
187. Gizi A, Papassotiriou I, Apostolakou F, et al. Assessment of oxidative stress in patients with sickle cell disease: the gluta-thione system and the oxidant-antioxidant status. Blood Cells Mol Dis. 2011;46(3):220-225.
188. Perrin R, Briancon S, Jeandel C, et al. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. Gerontology. 1990;36(5-6):306-313.
189. Sandmand M, Bruunsgaard H, Kemp K, et al. High circulating levels of tumor necrosis factor-alpha in centenarians are not associated with increased production in T lymphocytes. Gerontology. 2003;49(3):155-160.
190. Forsey RJ, Thompson JM, Ernerudh J, et al. Plasma cytokine profiles in elderly humans. Mech Ageing Dev. 2003;124(4):487-493.
191. Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JB, et al. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med. 2003;115(4):278-283.
192. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleu-kin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5(4):e78. (doi:10.1371/journal.pmed.0050078).
193. Jobs E, Ingelsson E, Riserus U, et al. Association between serum cathepsin S and mortality in older adults. JAMA. 2011;306(10):1113-1121.
194. Sakkinen PA, Cushman M, Psaty BM, et al. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol. 1999;19(3):499-504.
195. Modesti PA, Fortini A, Abbate R, et al. Age related changes of platelet prostacyclin receptors in humans. Eur J Clin Invest. 1985;15(4):204-208.
196. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembo-lism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113(8):636-642.
197. Mari D, Mannucci PM, Coppola R, et al. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995;85(11):3144-3149.
198. Silverstein RL, Bauer KA, Cushman M, et al. Venous thrombosis in the elderly: more questions than answers. Blood. 2007;110(9):3097-3101.
199. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15.
200. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost. 2004;2(2):281-288.
201. Dielis AW, Castoldi E, Spronk HM, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008;6(1):125-131.
202. Morbach H, Eichhorn EM, Liese JG, et al. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol. 2010;162(2):271-279.
203. Agrawal A, Agrawal S, Cao JN, et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol. 2007;178(11):6912-6922.
204. Hildebrandt P, Collinson PO, Doughty RN, et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J. 2010;31(15):1881-1889.
205. Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue Int. 2001;69(4):229-234.
206. Shahnazari M, Dwyer D, Chu V, et al. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone. 2012;50(3):628-637.
207. Yoshimura N, Muraki S, Oka H, et al. Changes in serum levels of biochemical markers of bone turnover during 10 years among Japanese men and women: associated factors and birth-cohort effect. The Taiji Study. J Bone Miner Metab. 2011;29(6):699-708.
208. Seibel MJ, Woitge HW. Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom. 1999;2(3):299-321.
209. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom. 1999; 2(3):323-342.
210. Delmas PD. Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis. Am J Med. 1993;95(5A):11S-16S.
211. Maimoun L, Fattal C, Sultan C. Bone remodeling and calcium homeostasis in patients with spinal cord injury: a review. Metabolism. 2011;60(12):1655-1663.